GlassScriptPhysician profile
Martha A Ball
NPI 1548677586
$3,482.39
in general payments reported to CMS, 2019-2025
30 companies · $54.69 in 2025
The $54.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,279 · 2022: $945 · 2023: $18.38 · 2024: $185 · 2025: $54.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.73 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $453.38 | 2021-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $370.64 | 2021-2022 | |
| Novo Nordisk INC | $241.37 | 2021 | |
| Amgen INC. | $204.94 | 2021-2022 | |
| Lilly USA, LLC | $170.61 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $160.97 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $156.19 | 2021 | |
| Esperion Therapeutics, INC. | $112.66 | 2021 | |
| Emmaus Medical, INC. | $105.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $103.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.89 | 2022 | |
| Upsher-Smith Laboratories LLC | $82.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.55 | 2021-2022 | |
| Corcept Therapeutics | $64.88 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $52.59 | 2021 | |
| Pfizer INC. | $51.20 | 2021-2022 | |
| Eisai INC. | $45.32 | 2021 | |
| Nestle Healthcare Nutrition INC. | $44.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.22 | 2021-2022 | |
| Horizon Therapeutics Plc | $38.48 | 2022-2023 | Krystexxa |
| Amarin Pharma, INC. | $37.64 | 2021 | |
| Ethicon US, LLC | $32.80 | 2022 | |
| Merck Sharp & Dohme LLC | $29.71 | 2021-2022 | |
| Mylan Specialty L.P. | $29.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.77 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $22.53 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.40 | 2021 | |
| Hologic Sales and Service, LLC | $11.21 | 2021 | |
| Genentech USA, INC. | $8.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.